<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021424</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068782</org_study_id>
    <secondary_id>NCI-01-DC-0006</secondary_id>
    <secondary_id>NCI-3210</secondary_id>
    <nct_id>NCT00021424</nct_id>
    <nct_alias>NCT00006410</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer</brief_title>
  <official_title>Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who&#xD;
      have stage IV head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxic effects of recombinant&#xD;
           fowlpox-TRICOM vaccine in patients with advanced squamous cell carcinoma of the oral&#xD;
           cavity or oropharynx or nodal or dermal metastases.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical activity of this regimen, in terms of inflammation at injection&#xD;
           site(s) and disease regression or stabilization, in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive recombinant fowlpox-TRICOM vaccine (rF-TRI) intralesionally once on weeks 0,&#xD;
      3, and 8. Beginning on week 16, patients may receive additional rF-TRI once every 8 weeks in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of rF-TRI until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox-TRICOM vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV squamous cell carcinoma of the oral cavity or&#xD;
             oropharynx or nodal or dermal metastases for which current available treatment is not&#xD;
             likely to offer a survival advantage or result in significant palliation&#xD;
&#xD;
               -  Unresectable locoregional recurrence after maximum radiotherapy OR&#xD;
&#xD;
               -  Local disease with unresectable distant metastases involving:&#xD;
&#xD;
                    -  Base of skull&#xD;
&#xD;
                    -  Prevertebral fascia&#xD;
&#xD;
                    -  Deep neck muscles&#xD;
&#xD;
                    -  Carotid artery (requiring resection)&#xD;
&#xD;
                    -  Nasopharynx and/or pterygoid muscles&#xD;
&#xD;
          -  Ineligible to receive radiotherapy to head and neck during study&#xD;
&#xD;
          -  Primary intraoral lesions must be measurable and accessible to intralesional&#xD;
             injections&#xD;
&#xD;
          -  No metastatic brain lesions, cerebral metastasis, or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 4 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT/PTT less than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No evidence of congestive heart failure&#xD;
&#xD;
          -  No serious cardiac dysrhythmia&#xD;
&#xD;
          -  No evidence of recent prior myocardial infarction on EKG&#xD;
&#xD;
          -  No clinical coronary artery disease&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No history of seizures or concurrent seizure disorder&#xD;
&#xD;
          -  No evidence of encephalitis, multiple sclerosis, or other structural brain lesion(s)&#xD;
             by clinical or radiological evaluation&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No risk of immune system compromise&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No hypersensitivity to eggs&#xD;
&#xD;
          -  No significant history of allergies (e.g., anaphylaxis or angioedema)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active or chronic infection&#xD;
&#xD;
          -  No other serious concurrent medical illness&#xD;
&#xD;
          -  No other malignancy unless previously treated with curative intent and no evidence of&#xD;
             persistent or recurrent disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior systemic corticosteroids&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to more than 50% of nodal groups&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  More than 4 weeks since prior surgery for primary or metastatic lesions and recovered&#xD;
&#xD;
          -  No prior splenectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Rudy, MSN</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute on Deafness and Other Communication Disorders (NIDCD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>skin metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

